“…The polymorphism of FAs is mainly attributed to their conformational flexibility and sometimes the participation of other weak intermolecular interactions. , The isosteric compounds of FAs, i.e., phenylaminonicotinic acids (PNAs), are also prone to exist in multiple forms in the solid state, as suggested by the polymorphism of a series of compounds including clonixin (CLX), niflumic acid (NFA), , 2-phenylaminonicotinic acid (2-PNA), − 2-(methyl-phenyl-amino)-nicotinic acid (2-MPNA), and other compounds, , due to both conformational flexibility and synthon variation (Scheme ). Recently, CLX was found to form solvates with N , N -dimethylformamide and its analogues. Polymorphism as a phenomenon is widely observed in molecular compounds and is of particular significance in pharmaceuticals because different forms of the same active pharmaceutical ingredient (API) may have different properties, e.g., kinetic, thermodynamic, surface, mechanical, and packaging, which can affect clinical formulation and eventual bioavailability. Meanwhile, polymorphism is also important theoretically, as demonstrated by a series of crystal structure prediction (CSP) tests. …”